Ocumension Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Ocumension Therapeutics has a total shareholder equity of CN¥2.8B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥3.0B and CN¥257.7M respectively.

Key information

0%

Debt to equity ratio

CN¥0

Debt

Interest coverage ration/a
CashCN¥972.91m
EquityCN¥2.77b
Total liabilitiesCN¥257.68m
Total assetsCN¥3.03b

Recent financial health updates

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29
Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14
Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

Aug 29
Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Jul 13
We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Jun 02
Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Jan 20
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Sep 27
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23
Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Financial Position Analysis

Short Term Liabilities: 1477's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥224.9M).

Long Term Liabilities: 1477's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥32.7M).


Debt to Equity History and Analysis

Debt Level: 1477 is debt free.

Reducing Debt: 1477 currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1477 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 1477 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 01:38
End of Day Share Price 2025/01/06 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocumension Therapeutics is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yanyin ZhuChina International Capital Corporation Limited
Fang QuanChina International Capital Corporation Limited
Ziyi ChenGoldman Sachs